Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)
Status:
Completed
Trial end date:
2019-09-10
Target enrollment:
Participant gender:
Summary
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of
Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder
Compared with Advair Diskus® 100/50 in Subjects with Asthma
Phase:
N/A
Details
Lead Sponsor:
West-Ward Pharmaceutical
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance